Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Fraxinus velutina pollen is a biologic allergenic extract derived from the pollen of the velvet ash tree (Fraxinus velutina), also known as the Arizona ash. [1] Developed by ALK-Abello, Inc., it is used for both the diagnosis and treatment of individuals with immediate hypersensitivity (Type I) allergies to this specific pollen. [16] For diagnosis, it is administered via percutaneous (prick) or intradermal skin tests to confirm sensitivity. [16] For treatment, it is used in allergen immunotherapy, administered through subcutaneous injections, to desensitize the patient's immune system and reduce allergic symptoms over time. [16] As a member of the Oleaceae family, Fraxinus velutina pollen can cause cross-reactivity in individuals allergic to olive tree pollen. [19] A specific formulation under NDC code 0268-1017-50 was previously available as a multi-dose vial, but this listing certification has since expired.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Fraxinus velutina pollen.